⌘K
Loading ticker…
Coherus Oncology, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Coherus Oncology, Inc. Common Stock (CHRS) has a 3-month relative strength percentile of 26 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 55. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.9%, relative volume 5.48×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
26 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
CHRS is in a stage 3 topping pattern, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -7.6% / -6.8%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
CHRS is held by 4 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $6M notional. Top 3 carry $13M.
Top 4 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $6M |
| IWMiShares Russell 2000 ETF | 0.01% | $4M |
| VXFVanguard Extended Market ETF | 0.00% | $3M |
| IWOiShares Russell 2000 Growth ETF | 0.00% | $433K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CHRS Jan avg: 2.31% median: -3.71% win: 50% σ: 37.46% n: 4 2022-04-12 → 2026-05-29 | CHRS Feb avg: -10.68% median: -13.05% win: 25% σ: 13.37% n: 4 2022-04-12 → 2026-05-29 | CHRS Mar avg: -5.06% median: 1.12% win: 75% σ: 14.93% n: 4 2022-04-12 → 2026-05-29 | CHRS Apr avg: -1.06% median: 5.03% win: 60% σ: 21.20% n: 5 2022-04-12 → 2026-05-29 | CHRS May avg: -20.83% median: -18.80% win: 0% σ: 14.34% n: 5 2022-04-12 → 2026-05-29 | CHRS Jun avg: -2.01% median: -3.15% win: 25% σ: 4.73% n: 4 2022-04-12 → 2026-05-29 (current) | CHRS Jul avg: 11.86% median: 14.94% win: 75% σ: 16.61% n: 4 2022-04-12 → 2026-05-29 | CHRS Aug avg: 14.05% median: 16.98% win: 75% σ: 18.14% n: 4 2022-04-12 → 2026-05-29 | CHRS Sep avg: -6.92% median: -19.61% win: 25% σ: 32.87% n: 4 2022-04-12 → 2026-05-29 | CHRS Oct avg: -11.46% median: -9.95% win: 25% σ: 12.70% n: 4 2022-04-12 → 2026-05-29 | CHRS Nov avg: -3.21% median: -20.10% win: 25% σ: 45.31% n: 4 2022-04-12 → 2026-05-29 | CHRS Dec avg: 22.33% median: 14.28% win: 100% σ: 23.16% n: 4 2022-04-12 → 2026-05-29 |